The goal of the Vanderbilt-Meharry HIV Immunopathogenesis core laboratory is to take advantage of recent? advances in technology related to the study of immune function in order to advance our understanding of? HIV immunopathogenesis. During the first 2 years of the Vanderbilt-Meharry D-CFAR term, the? Immunopathogenesis Core (Core D) has supported a multi-disciplinary environment that promotes basic,? clinical and translational HIV research. CFAR investigators now have access to state of the art flow? cytometry sorting capabilities and advanced fluorescence microscopy in a safe BL3 environment. We have? hired experienced staff, and have instituted seamless charge-back mechanisms that allow easy access to? our facilities.? Another strength of this core facility is the tight integration with the clinical discovery core and the virology? core. The access to clinical specimens through the clinical discovery core, and the wealth of experience in? clinical specimen processing by all the core directors, has made clinical specimens available for use by? CFAR investigators. This has provided basic scientists at Vanderbilt and Meharry the opportunity to perform? translational research. The immunopathogenesis core laboratory also offers training in state of the art? immune function assays, and access to BL3 hood space. This allows for rapid preparation of samples, and? direct access to the flow sorter and microscopy station.? The objectives of this CFAR core laboratory are to provide immunology-related services and support to all? CFAR investigators.
These specific aims i nclude: 1. To provide high-quality sorting of biohazardous cells? and flow cytometry to CFAR investigators. 2. To provide expertise, consultation, assay performance, and? training in immunology techniques including those that require BL3 procedures. 3. To provide unique? cellular imaging capabilities to CFAR investigators: 4. To aid in processing and storage of PBMC for CFAR? investigators: Our recent implementation of leukapheresis of HIV-infected subjects for targeted cohort? studies will ensure access to samples by several investigators. 5. To stimulate collaborations on HIV? immunopathogenesis among Vanderbilt and Meharry investigators. The immunopathogenesis core? laboratory has already fostered new interactions between D-CFAR members, and will further enhance? collaboration with this proposal.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI054999-06
Application #
7676756
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
6
Fiscal Year
2008
Total Cost
$259,197
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Liu, Qi; Li, Chun; Wanga, Valentine et al. (2018) Covariate-adjusted Spearman's rank correlation with probability-scale residuals. Biometrics 74:595-605
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Fritz, Cristin Q; Blevins, Meridith; Lindegren, Mary Lou et al. (2017) Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014. J Int AIDS Soc 20:20933
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Nicholas, Katherine J; Flaherty, David K; Smith, Rita M et al. (2017) Chronic HIV-1 Infection Impairs Superantigen-Induced Activation of Peripheral CD4+CXCR5+PD-1+ Cells, With Relative Preservation of Recall Antigen-Specific Responses. J Acquir Immune Defic Syndr 74:72-80
Drozd, Daniel R; Kitahata, Mari M; Althoff, Keri N et al. (2017) Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr 75:568-576
Muzaale, A D; Althoff, K N; Sperati, C J et al. (2017) Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors. Am J Transplant 17:1823-1832
Nicholas, Katherine J; Greenplate, Allison R; Flaherty, David K et al. (2016) Multiparameter analysis of stimulated human peripheral blood mononuclear cells: A comparison of mass and fluorescence cytometry. Cytometry A 89:271-80
May, Margaret T; Vehreschild, Jorg-Janne; Trickey, Adam et al. (2016) Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clin Infect Dis 62:1571-1577

Showing the most recent 10 out of 203 publications